<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620373</url>
  </required_header>
  <id_info>
    <org_study_id>1337-05 Part A</org_study_id>
    <secondary_id>Susan G. Komen Foundation</secondary_id>
    <nct_id>NCT00620373</nct_id>
  </id_info>
  <brief_title>Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts</brief_title>
  <official_title>Evaluation of Low-dose Molecular Breast Imaging as a Screening Tool in Women With Mammographically Dense Breasts and Increased Risk of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Susan G. Komen Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to compare the sensitivity of mammography to the sensitivity of Molecular Breast
      Imaging (a new gamma-camera based breast imaging technology) in women with dense breast
      tissue who are at increased risk for breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sensitivity of conventional mammography (MMO) is poor in women with mammographically
      dense breast parenchyma. We have developed Molecular Breast Imaging (MBI) - a new technique
      which utilizes a Cadmium-Zinc-Telluride (CZT) gamma camera for scintimammography that has a
      high sensitivity (~90%) for the detection of breast cancers independent of breast density.

      The aim of this study is to demonstrate the utility of MBI as an adjunct screening modality
      for the detection of occult breast cancers in women with mammographically dense breast
      tissue. Initial recruitment will be from the pool of patients awaiting a screening mammogram
      in the Department of Radiology at Mayo Clinic Rochester. All patients will have a screening
      MMO and an MBI study. Patients with positive studies (MBI or MMO) will undergo additional
      diagnostic studies. At 15 months post-recruitment, all patients will be contacted by phone or
      mail to determine whether subsequent to their study, there has been any change in their
      breast status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Yield</measure>
    <time_frame>12 months after mammography and gamma imaging</time_frame>
    <description>Diagnostic yield is the likelihood that a test or procedure will provide the information needed to establish a diagnosis. In this case, it is the proportion of women with positive results of a screening test and positive results with the reference standard (verified cancer status).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cancer Diagnosis at 12 Months</measure>
    <time_frame>12 months after mammography and gamma imaging</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>12 months after mammography and gamma imaging</time_frame>
    <description>Sensitivity measures the proportion of actual positives which are correctly identified as such.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>12 month after mammography and gamma imaging</time_frame>
    <description>Specificity measures the proportion of negatives which are correctly identified as such.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recall Rate</measure>
    <time_frame>12 months after mammography and gamma imaging</time_frame>
    <description>Recall rate was defined as the percentage of participants recalled for follow-up studies initiated because of abnormal findings with mammography or gamma imaging.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">969</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Mammography and Molecular Breast Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Molecular Breast Imaging</intervention_name>
    <description>Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.</description>
    <arm_group_label>Mammography and Molecular Breast Imaging</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional Mammography</intervention_name>
    <description>Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.</description>
    <arm_group_label>Mammography and Molecular Breast Imaging</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technetium (99mTc) sestamibi</intervention_name>
    <description>Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.</description>
    <arm_group_label>Mammography and Molecular Breast Imaging</arm_group_label>
    <other_name>Cardiolite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Past prior screening mammography (SM) interpreted as negative or benign (This
             screening must have been performed at Mayo Clinic Rochester, Minnesota).

          2. Past prior SM interpreted as heterogeneously dense or extremely dense (This screening
             must have been performed at Mayo Clinic Rochester, Minnesota).

          3. Women younger than 50 years who had not undergone prior mammography, as most of these
             women have dense breasts.

          4. Subjects had to have at least one of the following risk factors:

               1. Known mutation in breast cancer susceptibility gene 1 (BRCA1) or breast cancer
                  susceptibility gene 2 (BRCA2)

               2. History of chest, mediastinal, or axillary irradiation

               3. Personal history of breast cancer

               4. History of prior biopsy showing atypical ductal hyperplasia, atypical lobular
                  hyperplasia, lobular carcinoma in situ, or atypical papilloma

               5. Gail or Claus model lifetime risk greater than or equal to 20%

               6. Gail model 5 year risk greater or equal to 2.5%

               7. Gail model 5 year risk greater or equal to 1.6%

               8. One first-degree relative with history of breast cancer

               9. Two second-degree relatives with history of breast cancer

        Exclusion Criteria:

          1. They are unable to understand and sign the consent form

          2. They are pregnant or lactating

          3. They are physically unable to sit upright and still for 40 minutes.

          4. They have self-reported signs or symptoms of breast cancer (palpable mass, bloody
             nipple discharge, axillary mass etc.).

          5. They have had needle biopsy within 3 months, or breast surgery within 1 year prior to
             the study.

          6. They are currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor
             for adjuvant therapy or chemoprevention.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah J. Rhodes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.youtube.com/watch?v=DOQBLe8MdH0</url>
    <description>Mayo Clinic You Tube Channel</description>
  </link>
  <results_reference>
    <citation>Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology. 2011 Jan;258(1):106-18. doi: 10.1148/radiol.10100625. Epub 2010 Nov 2.</citation>
    <PMID>21045179</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <results_first_submitted>August 15, 2013</results_first_submitted>
  <results_first_submitted_qc>November 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2013</results_first_posted>
  <last_update_submitted>July 30, 2014</last_update_submitted>
  <last_update_submitted_qc>July 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Deborah Rhodes</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Dense breast tissue</keyword>
  <keyword>Breast Cancer Screening</keyword>
  <keyword>Molecular Breast Imaging</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled between September 2005 and February 2009 in Rochester, Minnesota.</recruitment_details>
      <pre_assignment_details>969 subjects completed imaging and met eligibility criteria, but 33 were excluded because of lack of the reference standard (unverified cancer status).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mammography and Molecular Breast Imaging</title>
          <description>Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ)(20-mCi) Technetium (99mTc) sestamibi injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="969"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="936"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unverified cancer status</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mammography and Molecular Breast Imaging</title>
          <description>Participants underwent conventional mammography and molecular breast imaging after a 740-mBQ (20-mCi) Technetium (99mTc) sestamibi injection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="969"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" lower_limit="25" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race or ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or data missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perimenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical menopause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mammographic breast density</title>
          <description>Eligibility was determined by density assessed on a previous mammogram prior to study entry; mammographic density reported refers to density assessed from the study mammogram.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Almost entirely fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scattered fibroglandular densities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heterogeneously dense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely dense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk factors</title>
          <description>Although participants may have qualified for multiple risk factor categories, they were assigned to only one risk factor category in this table. These risk factors are listed in order of priority. The last two risk factors with respect to first and second-degree relatives with a history of breast cancer refer to subjects who qualified on the basis of family history but did not meet the Gail or Claus model risk threshold levels.
The Gail risk model focuses on nongenetic risk factors, with limited information on family history. The Claus risk model focuses on genetic risk factors.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Known mutation in BRCA1 or BRCA2 gene</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior chest, mediastinal, or auxiliary irradiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior biopsy showing hyperplasia, etc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gail or Claus model lifetime risk ≥ 20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gail model 5 year risk ≥ 2.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gail model 5 year risk ≥ 1.6%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 first-deg relative with history of breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 second-deg relatives history of breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>personal history of breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Yield</title>
        <description>Diagnostic yield is the likelihood that a test or procedure will provide the information needed to establish a diagnosis. In this case, it is the proportion of women with positive results of a screening test and positive results with the reference standard (verified cancer status).</description>
        <time_frame>12 months after mammography and gamma imaging</time_frame>
        <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging).</population>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Gamma Imaging</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
          <group group_id="O3">
            <title>Both Mammography and Gamma Imaging</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and gamma images together.</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Yield</title>
          <description>Diagnostic yield is the likelihood that a test or procedure will provide the information needed to establish a diagnosis. In this case, it is the proportion of women with positive results of a screening test and positive results with the reference standard (verified cancer status).</description>
          <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging).</population>
          <units>cancers per 1000 women screened</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="936"/>
                <count group_id="O2" value="936"/>
                <count group_id="O3" value="936"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.1" upper_limit="9.4"/>
                    <measurement group_id="O2" value="9.6" lower_limit="5.1" upper_limit="18.2"/>
                    <measurement group_id="O3" value="10.7" lower_limit="5.8" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.016</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.07</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity</title>
        <description>Sensitivity measures the proportion of actual positives which are correctly identified as such.</description>
        <time_frame>12 months after mammography and gamma imaging</time_frame>
        <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging).</population>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Gamma Imaging</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
          <group group_id="O3">
            <title>Both Mammography and Gamma Imaging</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and gamma images together.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity</title>
          <description>Sensitivity measures the proportion of actual positives which are correctly identified as such.</description>
          <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging).</population>
          <units>number of cancers diagnosed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All cancers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="9.7" upper_limit="56.6"/>
                    <measurement group_id="O2" value="9" lower_limit="52.3" upper_limit="94.9"/>
                    <measurement group_id="O3" value="10" lower_limit="62.3" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Invasive cancers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="8.2" upper_limit="64.1"/>
                    <measurement group_id="O2" value="7" lower_limit="64.6" upper_limit="100"/>
                    <measurement group_id="O3" value="7" lower_limit="64.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ductal carcinoma in situ (DCIS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="4.6" upper_limit="69.9"/>
                    <measurement group_id="O2" value="2" lower_limit="15.0" upper_limit="85.0"/>
                    <measurement group_id="O3" value="3" lower_limit="30.0" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For all cancers; significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.016</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For all cancers; significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.07</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For invasive cancers; significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.063</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For invasive cancers; significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.063</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For ductal carcinoma in situ; significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.5</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For ductal carcinoma in situ; significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.99</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cancer Diagnosis at 12 Months</title>
        <time_frame>12 months after mammography and gamma imaging</time_frame>
        <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging).</population>
        <group_list>
          <group group_id="O1">
            <title>Mammography and Molecular Breast Imaging</title>
            <description>Participants underwent conventional mammography and molecular breast imaging after a 740-mBQ (20-mCi) Technetium (99mTc) sestamibi injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cancer Diagnosis at 12 Months</title>
          <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="936"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Invasive cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ductal carcinoma in situ (DCIS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specificity</title>
        <description>Specificity measures the proportion of negatives which are correctly identified as such.</description>
        <time_frame>12 month after mammography and gamma imaging</time_frame>
        <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging). The number of participants negative for breast cancer was 936-11 = 925.</population>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Gamma Imaging</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
          <group group_id="O3">
            <title>Both Mammography and Gamma Imaging</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and gamma images together.</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity</title>
          <description>Specificity measures the proportion of negatives which are correctly identified as such.</description>
          <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging). The number of participants negative for breast cancer was 936-11 = 925.</population>
          <units>number of true negatives</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="925"/>
                <count group_id="O2" value="925"/>
                <count group_id="O3" value="925"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="840" lower_limit="88.8" upper_limit="92.5"/>
                    <measurement group_id="O2" value="861" lower_limit="91.3" upper_limit="94.5"/>
                    <measurement group_id="O3" value="788" lower_limit="82.8" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.069</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recall Rate</title>
        <description>Recall rate was defined as the percentage of participants recalled for follow-up studies initiated because of abnormal findings with mammography or gamma imaging.</description>
        <time_frame>12 months after mammography and gamma imaging</time_frame>
        <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging).</population>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Gamma Imaging</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
          <group group_id="O3">
            <title>Both Mammography and Gamma Imaging</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and gamma images together.</description>
          </group>
        </group_list>
        <measure>
          <title>Recall Rate</title>
          <description>Recall rate was defined as the percentage of participants recalled for follow-up studies initiated because of abnormal findings with mammography or gamma imaging.</description>
          <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and gamma imaging).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="936"/>
                <count group_id="O2" value="936"/>
                <count group_id="O3" value="936"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7.7" upper_limit="11.4"/>
                    <measurement group_id="O2" value="8" lower_limit="6.1" upper_limit="9.5"/>
                    <measurement group_id="O3" value="15" lower_limit="13.1" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.218</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for adverse events while they were on the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mammography and Molecular Breast Imaging</title>
          <description>Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ)(20-mCi) Technetium (99mTc) sestamibi injection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Deborah J. Rhodes</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-538-1703</phone>
      <email>rhodes.deborah@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

